{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T21:07:13Z","timestamp":1789247233151,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40121-026-01412-6","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T10:43:28Z","timestamp":1784630608000},"page":"2589-2607","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide or Entecavir in Older Patients with Chronic Hepatitis\u00a0B"],"prefix":"10.1007","volume":"15","author":[{"given":"Federico","family":"Cesanelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ottavia","family":"Nozza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Gottardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Mosti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Zaltron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Tiecco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Scarvaglieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angiola","family":"Spinetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Castelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1452-9100","authenticated-orcid":false,"given":"Eugenia","family":"Quiros-Roldan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"1412_CR1","unstructured":"WHO. Global hepatitis report 2024. 2024. https:\/\/www.who.int\/publications\/i\/item\/9789240091672. Accessed 24 Mar 2026."},{"key":"1412_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.03.018","author":"European Association for the Study of the Liver","year":"2025","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines on the management of hepatitis\u00a0B virus infection. J Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.jhep.2025.03.018.","journal-title":"J Hepatol"},{"key":"1412_CR3","doi-asserted-by":"publisher","unstructured":"Terrault NA, Lok ASF, McMahon BJ Jr, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis\u00a0B: AASLD 2018\u00a0hepatitis\u00a0B guidance. Hepatology. 2018.https:\/\/doi.org\/10.1002\/hep.29800.","DOI":"10.1002\/hep.29800"},{"key":"1412_CR4","doi-asserted-by":"publisher","DOI":"10.1086\/655681","author":"RD Cooper","year":"2010","unstructured":"Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010. https:\/\/doi.org\/10.1086\/655681.","journal-title":"Clin Infect Dis"},{"key":"1412_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2022.09.021","author":"X Yang","year":"2022","unstructured":"Yang X, Yan H, Zhang X, Qin X, Guo P. Comparison of renal safety and bone mineral density of tenofovir and entecavir in patients with chronic hepatitis\u00a0B: a systematic review and meta-analysis. Int J Infect Dis. 2022. https:\/\/doi.org\/10.1016\/j.ijid.2022.09.021.","journal-title":"Int J Infect Dis"},{"key":"1412_CR6","doi-asserted-by":"publisher","unstructured":"Mak LY, Hu TH, Yap DYH. Review article: renal safety profiles of tenofovir alafenamide, tenofovir disoproxil fumarate, and entecavir for the treatment of chronic hepatitis\u00a0B infection-general and special populations. Aliment Pharmacol Ther. 2026. https:\/\/doi.org\/10.1111\/apt.70560.","DOI":"10.1111\/apt.70560"},{"key":"1412_CR7","doi-asserted-by":"publisher","unstructured":"Hall AM, Hendry BM, Nitsch D, Connolly JO. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis. 2011. https:\/\/doi.org\/10.1053\/j.ajkd.2011.01.022.","DOI":"10.1053\/j.ajkd.2011.01.022"},{"key":"1412_CR8","doi-asserted-by":"publisher","unstructured":"Buti M, Gane E, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis\u00a0B virus infection: a randomised, double-blind, phase\u00a03, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016. https:\/\/doi.org\/10.1016\/S2468-1253(16)30107-8. (Erratum in: Lancet Gastroenterol Hepatol. 2016. https:\/\/doi.org\/10.1016\/S2468-1253(16)30128-5).","DOI":"10.1016\/S2468-1253(16)30107-8"},{"key":"1412_CR9","doi-asserted-by":"publisher","unstructured":"Kaneko S, Kurosaki M, Tamaki N, et al. Tenofovir alafenamide for hepatitis\u00a0B virus infection including switching therapy from tenofovir disoproxil fumarate. J Gastroenterol Hepatol. 2019. https:\/\/doi.org\/10.1111\/jgh.14686.","DOI":"10.1111\/jgh.14686"},{"key":"1412_CR10","doi-asserted-by":"publisher","unstructured":"Wang L, Pi G, Lu D, Wang Y, Sun W. A retrospective comparative study of tenofovir alafenamide and tenofovir disoproxil fumarate in chronic hepatitis\u00a0B patients: renal and bone safety versus antiviral efficacy. Medicine (Baltimore). 2026. https:\/\/doi.org\/10.1097\/MD.0000000000047350.","DOI":"10.1097\/MD.0000000000047350"},{"key":"1412_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31793","author":"H Toyoda","year":"2021","unstructured":"Toyoda H, Leong J, Landis C, et al. Treatment and renal outcomes up to 96\u00a0weeks after tenofovir alafenamide switch from tenofovir disoproxil fumarate in routine practice. Hepatology. 2021. https:\/\/doi.org\/10.1002\/hep.31793.","journal-title":"Hepatology"},{"key":"1412_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-08023-0","author":"H Kim","year":"2025","unstructured":"Kim H, Kim JY, Yoo HJ, Kim LY, Yoo JJ, Kim YS. Nationwide analysis of renal outcomes in chronic hepatitis\u00a0B patients treated with tenofovir alafenamide vs. entecavir. Sci Rep. 2025. https:\/\/doi.org\/10.1038\/s41598-025-08023-0.","journal-title":"Sci Rep"},{"key":"1412_CR13","doi-asserted-by":"publisher","unstructured":"Santos JR, Saumoy M, Curran A, et al. Tenofovir\/emtricitabine inflUence on LIPid metabolism (TULIP) Study Group. The lipid-lowering effect of tenofovir\/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial. Clin Infect Dis. 2015. https:\/\/doi.org\/10.1093\/cid\/civ296.","DOI":"10.1093\/cid\/civ296"},{"key":"1412_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-023-10528-7","author":"EG Hwang","year":"2023","unstructured":"Hwang EG, Jung EA, Yoo JJ, Kim SG, Kim YS. Risk of dyslipidemia in chronic hepatitis\u00a0B patients taking tenofovir alafenamide: a systematic review and meta-analysis. Hepatol Int. 2023. https:\/\/doi.org\/10.1007\/s12072-023-10528-7.","journal-title":"Hepatol Int"},{"key":"1412_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0261760","author":"K Suzuki","year":"2022","unstructured":"Suzuki K, Suda G, Yamamoto Y, et al. Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis\u00a0B. PLoS ONE. 2022. https:\/\/doi.org\/10.1371\/journal.pone.0261760.","journal-title":"PLoS ONE"},{"key":"1412_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1604972","author":"YH Zhou","year":"2025","unstructured":"Zhou YH, Cai N, Chen YX, Su YL, Hu P. Metabolic effects and cardiovascular disease risks of TDF or TAF in patients with chronic hepatitis\u00a0B: a systematic review and meta-analysis. Front Pharmacol. 2025. https:\/\/doi.org\/10.3389\/fphar.2025.1604972.","journal-title":"Front Pharmacol"},{"key":"1412_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29760","author":"H Shin","year":"2024","unstructured":"Shin H, Lim GS, Yoon JW, et al. Metabolic effects and cardiovascular disease risks of antiviral treatments in patients with chronic hepatitis\u00a0B. J Med Virol. 2024. https:\/\/doi.org\/10.1002\/jmv.29760.","journal-title":"J Med Virol"},{"key":"1412_CR18","unstructured":"Agenzia Italiana del Farmaco (AIFA). Piano terapeutico per la prescrizione di Vemlidy (tenofovir alafenamide). Gazzetta Ufficiale della Repubblica Italiana; 2026. Available from: https:\/\/www.gazzettaufficiale.it\/. Accessed 9 July 2026."},{"key":"1412_CR19","unstructured":"Roche Diagnostics.\u00a0cobas HBV: Quantitative nucleic acid test for use on the cobas 6800\/8800 Systems\u00a0[Instructions for Use]. Basel, Switzerland: Roche Diagnostics; 2020."},{"key":"1412_CR20","unstructured":"R Core Team.\u00a0R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2024.\u00a0https:\/\/www.R-project.org."},{"key":"1412_CR21","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02483-13","author":"JH Lee","year":"2014","unstructured":"Lee JH, Cho Y, Lee DH, et al. Prior exposure to lamivudine increases entecavir resistance risk in chronic hepatitis\u00a0B patients without detectable lamivudine resistance. Antimicrob Agents Chemother. 2014. https:\/\/doi.org\/10.1128\/AAC.02483-13.","journal-title":"Antimicrob Agents Chemother"},{"key":"1412_CR22","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2015.21.2.131","author":"JA Hwang","year":"2015","unstructured":"Hwang JA, Kim KB, Yang MJ, et al. Impact of prior lamivudine use on the antiviral efficacy and development of resistance to entecavir in chronic hepatitis\u00a0B patients. Clin Mol Hepatol. 2015. https:\/\/doi.org\/10.3350\/cmh.2015.21.2.131.","journal-title":"Clin Mol Hepatol"},{"key":"1412_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2012.65","author":"RJ Glassock","year":"2012","unstructured":"Glassock RJ, Rule AD. The implications of anatomical and functional changes of the aging kidney: with an emphasis on the glomeruli. Kidney Int. 2012. https:\/\/doi.org\/10.1038\/ki.2012.65.","journal-title":"Kidney Int"},{"key":"1412_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1143346","author":"S Zaltron","year":"2023","unstructured":"Zaltron S, Cambianica A, Di Gregorio M, et al. Case report: an occult hepatitis\u00a0B virus infection reactivation in an HIV\/HCV coinfected patient during an immune reconstitution inflammatory syndrome. Front Cell Infect Microbiol. 2023. https:\/\/doi.org\/10.3389\/fcimb.2023.1143346.","journal-title":"Front Cell Infect Microbiol"},{"key":"1412_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0098865","author":"W Ke","year":"2014","unstructured":"Ke W, Liu L, Zhang C, et al. Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis\u00a0B virus infection: a systematic review and meta-analysis. PLoS ONE. 2014. https:\/\/doi.org\/10.1371\/journal.pone.0098865.","journal-title":"PLoS ONE"},{"key":"1412_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/life15040672","author":"MA De Francesco","year":"2025","unstructured":"De Francesco MA, Gargiulo F, Dello Iaco F, et al. Immune escape and drug resistance mutations in patients with hepatitis\u00a0B virus infection: clinical and epidemiological implications. Life. 2025. https:\/\/doi.org\/10.3390\/life15040672.","journal-title":"Life"},{"key":"1412_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0324897","author":"W Praguylertluck","year":"2025","unstructured":"Praguylertluck W, Kaewdech A, Chamroonkul N, Piratvisuth T, Sripongpun P. Effect of switching from prior nucleos(t)ide analogue(s) to tenofovir alafenamide on lipid profile and cardiovascular risk in patients with chronic hepatitis\u00a0B. PLoS ONE. 2025. https:\/\/doi.org\/10.1371\/journal.pone.0324897.","journal-title":"PLoS ONE"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01412-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01412-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01412-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T20:41:30Z","timestamp":1789245690000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-026-01412-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1412"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01412-6","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"1 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Federico Cesanelli, Ottavia Nozza, Federica Gottardi, Francesca Mosti, Serena Zaltron, Giorgio Tiecco, Irene Scarvaglieri, Angiola Spinetti, Francesco Castelli, and Eugenia Quiros-Roldan have nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Comitato Etico Territoriale Lombardia 6, Fondazione I.R.C.C.S. Policlinico San Matteo, 27100\u00a0Pavia, Italy (protocol number 0038573\/24, 25 June 2024), and conducted in accordance with the ethical standards of the Helsinki Declaration (1975, revised in 2013).","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}